Clinical Trials
72 trialsNCT07143669 2026-05-22
Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
Blueprint Medicines Corporation
Recruiting
NCT07454850 2026-05-18
A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait
Novartis
Not yet recruiting
NCT07549516 2026-05-15
ASC2ADHERE
Novartis
Recruiting
NCT07264959 2026-04-22
An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)
Blueprint Medicines Corporation
Recruiting
NCT05943522 2026-04-20
Asciminib RMP Study
Novartis
Recruiting
NCT07255638 2026-04-20
A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany
Blueprint Medicines Corporation
Recruiting
NCT06297161 2026-04-14
A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).
Pfizer
Recruiting
NCT04635384 2026-03-18
ACROBAT
CareDx
Active not recruiting
NCT06092879 2026-02-06
ASSURE-3
Novartis
Active not recruiting
NCT06743035 2026-01-09
ROPE
iOMEDICO AG
Recruiting
NCT03452774 2025-10-28
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
Recruiting
NCT07188428 2025-09-23
Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment
Novartis
Completed
NCT05548062 2025-09-03
Prospero
Novartis
Active not recruiting
NCT07151820 2025-09-03
A Real-world Study About the Impact of Adverse Events (AEs) on Treatment Adjustments, Healthcare Resource Use, and Costs Among Chronic Myeloid Leukemia Patients
Novartis
Completed
NCT07150793 2025-09-02
A Study of Real-world Treatment and Burden of Chronic Myeloid Leukemia Patients in Japan
Novartis
Completed
NCT07145411 2025-08-28
HOPE
Ossium Health, Inc.
Recruiting
NCT01688011 2025-07-03
Connect® Myeloid Disease Registry
Celgene
Terminated
NCT05282108 2025-03-26
CARCML
Hikma Pharmaceuticals LLC
Recruiting
NCT05735704 2025-03-26
SANGUINE
JaxBio Ltd
Unknown
NCT04036448 2025-03-11
RevlimidPMS
Celgene
Completed
NCT04028479 2024-12-18
ROOT
Taproot Health
Completed
NCT06692803 2024-11-18
ABL-2022-03
Novartis
Completed
NCT03259230 2024-09-19
Evaluation of IFNγ and Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis
Swedish Orphan Biovitrum
Completed
NCT05645744 2024-07-22
Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
Mustang Bio
Terminated
NCT05853445 2024-05-06
PAVE
Novartis
Completed
NCT02501330 2024-04-30
BLF
Pfizer
Completed
NCT02455024 2024-04-04
OMNI
Takeda
Terminated
NCT05421091 2024-03-27
Special Drug Use-results Surveillance of Scemblix Tablets
Novartis
Completed
NCT05444972 2023-12-11
METER
AbbVie
Completed
NCT06148493 2023-11-28
Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims Database
Novartis
Completed
NCT05286528 2023-10-27
Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
Pfizer
Completed
NCT02546375 2023-10-03
A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands
Pfizer
Completed
NCT04048564 2023-09-28
Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®)
Incyte Corporation
Completed
NCT05734053 2023-08-21
NOFRETETE
Novartis
Completed
NCT05893836 2023-06-08
Real-World Disease Management and Outcomes in Chronic Myeloid Leukaemia
Novartis
Completed
NCT05218902 2023-05-31
DIM Vidaza
Bristol-Myers Squibb
Completed
NCT05611216 2023-04-06
Clinical Outcomes of 3L+ Therapies Among Patients With Chronic Myeloid Leukemia and Those With T315I Mutation
Novartis
Completed
NCT03709017 2022-12-07
Iclusig PMS in CML or Ph+ALL Patients
Korea Otsuka Pharmaceutical Co., Ltd.
Unknown
NCT05619978 2022-11-17
French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML Patients
Novartis
Completed
NCT05476562 2022-11-08
Study Conducted Among Patients With CML
Novartis
Completed
NCT05421104 2022-07-05
Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.
Novartis
Completed
NCT01244750 2022-06-30
SIMPLICITY
Bristol-Myers Squibb
Completed
NCT03509896 2022-06-27
Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Bristol-Myers Squibb
Completed
NCT04089839 2022-06-21
A Study of Dasatinib Management Among CP-CML (Chronic Phase, Chronic Myeloid Leukemia) Participants Initiating Dasatinib in a Real Life Setting
Bristol-Myers Squibb
Completed
NCT02921802 2022-06-14
A Study of Special Use Results Surveillance of Revlimid 5mg Capsules
Celgene
Completed
NCT02921815 2022-06-14
A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid Treatment
Celgene
Completed
NCT02953704 2022-05-13
Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)
Incyte Corporation
Completed
NCT03678454 2022-04-12
Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium
Incyte Corporation
Completed
NCT04014764 2022-04-05
(ANSWer)
Notable Labs
Completed
NCT04695431 2022-01-10
Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM
Blueprint Medicines Corporation
Completed